AU2007263237B2 - Adenosine A3 receptor agonists - Google Patents

Adenosine A3 receptor agonists Download PDF

Info

Publication number
AU2007263237B2
AU2007263237B2 AU2007263237A AU2007263237A AU2007263237B2 AU 2007263237 B2 AU2007263237 B2 AU 2007263237B2 AU 2007263237 A AU2007263237 A AU 2007263237A AU 2007263237 A AU2007263237 A AU 2007263237A AU 2007263237 B2 AU2007263237 B2 AU 2007263237B2
Authority
AU
Australia
Prior art keywords
alkyl
optionally
halo
nitrogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007263237A
Other languages
English (en)
Other versions
AU2007263237A1 (en
Inventor
Robin Alec Fairhurst
Roger John Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2007263237A1 publication Critical patent/AU2007263237A1/en
Application granted granted Critical
Publication of AU2007263237B2 publication Critical patent/AU2007263237B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2007263237A 2006-04-21 2007-04-19 Adenosine A3 receptor agonists Ceased AU2007263237B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0607944.6A GB0607944D0 (en) 2006-04-21 2006-04-21 Organic compounds
GB0607944.6 2006-04-21
PCT/EP2007/053847 WO2007147659A1 (en) 2006-04-21 2007-04-19 Adenosine a3 receptor agonists

Publications (2)

Publication Number Publication Date
AU2007263237A1 AU2007263237A1 (en) 2007-12-27
AU2007263237B2 true AU2007263237B2 (en) 2010-09-30

Family

ID=36581041

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007263237A Ceased AU2007263237B2 (en) 2006-04-21 2007-04-19 Adenosine A3 receptor agonists

Country Status (12)

Country Link
US (1) US20090281126A1 (enExample)
EP (1) EP2013199A1 (enExample)
JP (1) JP2009534358A (enExample)
KR (1) KR20080110845A (enExample)
CN (1) CN101426785A (enExample)
AU (1) AU2007263237B2 (enExample)
BR (1) BRPI0710514A2 (enExample)
CA (1) CA2649648A1 (enExample)
GB (1) GB0607944D0 (enExample)
MX (1) MX2008013520A (enExample)
RU (1) RU2008145708A (enExample)
WO (1) WO2007147659A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
WO2007121920A2 (en) 2006-04-21 2007-11-01 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
US20100041918A1 (en) * 2006-11-10 2010-02-18 Novartis Ag Cyclopentene diol monoacetate derivatives
CN101827847A (zh) * 2007-10-17 2010-09-08 诺瓦提斯公司 用作腺苷a1受体配体的嘌呤衍生物
WO2009123881A1 (en) 2008-03-31 2009-10-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 receptor- selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
US8796291B2 (en) 2008-08-01 2014-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005298979A1 (en) * 2004-10-25 2006-05-04 Unilever Plc Quaternary ammonium salts as anti-aging actives in personal care compositions

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1528382A (en) * 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
BR9612341A (pt) * 1996-01-02 1999-12-28 Rhone Poulenc Rorer Pharma Processo para preparar 2,4-diidróxipiridina.
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
KR20010089751A (ko) * 1998-12-31 2001-10-08 오흘러 로스 제이. Ｎ6-치환된 데아자-아데노신 유도체의 제조방법
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
BR0206492A (pt) * 2001-01-16 2004-02-10 Can Fite Biopharma Ltd Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em células
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
US7414036B2 (en) * 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
PL1699459T3 (pl) * 2003-12-29 2007-12-31 Can Fite Biopharma Ltd Sposób leczenia stwardnienia rozsianego
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
EP1778239B1 (en) * 2004-07-28 2013-08-21 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
CN101056879B (zh) * 2004-09-09 2011-10-05 美国政府卫生与公共服务部 作为a3和a1腺苷受体激动剂的嘌呤衍生物
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US20080051364A1 (en) * 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
EP1848718B1 (en) * 2005-02-04 2012-08-01 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
CA2622879C (en) * 2005-11-30 2011-07-05 Can-Fite Biopharma Ltd. Use of a3 adenosine receptor agonist in osteoarthritis treatment
DK1983990T3 (da) * 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
CN106008512B (zh) * 2006-02-02 2019-03-12 千禧药品公司 E1活化酶抑制剂
WO2007121920A2 (en) * 2006-04-21 2007-11-01 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
US20100041918A1 (en) * 2006-11-10 2010-02-18 Novartis Ag Cyclopentene diol monoacetate derivatives
US20090181934A1 (en) * 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
CN101827847A (zh) * 2007-10-17 2010-09-08 诺瓦提斯公司 用作腺苷a1受体配体的嘌呤衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005298979A1 (en) * 2004-10-25 2006-05-04 Unilever Plc Quaternary ammonium salts as anti-aging actives in personal care compositions

Also Published As

Publication number Publication date
AU2007263237A1 (en) 2007-12-27
EP2013199A1 (en) 2009-01-14
GB0607944D0 (en) 2006-05-31
CA2649648A1 (en) 2007-12-27
MX2008013520A (es) 2008-10-29
WO2007147659A1 (en) 2007-12-27
BRPI0710514A2 (pt) 2011-08-16
JP2009534358A (ja) 2009-09-24
RU2008145708A (ru) 2010-05-27
US20090281126A1 (en) 2009-11-12
KR20080110845A (ko) 2008-12-19
CN101426785A (zh) 2009-05-06

Similar Documents

Publication Publication Date Title
AU2007263237B2 (en) Adenosine A3 receptor agonists
AU2015225745B2 (en) Heterocyclic compounds
CN101056879B (zh) 作为a3和a1腺苷受体激动剂的嘌呤衍生物
JP4202421B2 (ja) 抗高血圧、心臓保護、抗乏血及び抗脂肪分解特性を有する化合物
JP2018527309A (ja) ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン
JP2001522858A (ja) 化合物
AU2016355654A1 (en) Inhibitors of CXCR2
AU2008313789A1 (en) Purine derivatives as adenosine AL receptor ligands
SG189706A1 (en) 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TW201627309A (zh) Ｊａｋ抑制劑
JP2009529541A (ja) 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤
BRPI0710573A2 (pt) compostos orgánicos, usos e processos para a preparação dos referidos compostos, bem como composição farmacêutica compreendendo os mesmos
EP3226861A2 (en) Compounds for treating cystic fibrosis
KR20080081177A (ko) 야누스 키나아제 억제제인 술폰아미도아닐린 유도체
JP2007522160A (ja) ケモカインｃｃｒ５受容体モジュレーター
MX2013000389A (es) Compuestos de purina selectivos para fosfatidilinositol 3-cinasa p110 delta, y metodods de uso.
TW201315727A (zh) 尿嘧啶衍生物及其醫藥用途
JP7335644B2 (ja) ジヒドロピロロピリミジン系選択性ｊａｋ２阻害剤またはその薬理学的に許容される塩、その製造方法、医薬品、および、組成物
KR20170058406A (ko) 화합물 및 방법
JP2954971B2 (ja) 選択的アデノシン受容体剤
US7906518B2 (en) Therapeutic compounds
JP2004534002A (ja) 化合物
JP2019501949A (ja) アデノシンａ３受容体拮抗化合物、その調製方法、およびその医学的使用
EP3719013B1 (en) Pyrimidine sulfamide derivative and preparation method and medical application thereof
US8148385B2 (en) Substituted [1,2,3] triazolo[4,5-d]pyrimidine derivatives as ADP P2Y12 receptor antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired